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Background: Tyrosinemia type 1 (TT1) is an autosomal recessive disorder caused by deficiency of the enzyme
fumarylacetoacetate hydrolase (FAH). TT1 usually presents in infancy with features suggestive of liver disease or
with sepsis-like symptoms.
Case presentation: We report two Saudi siblings with TT1. Case 1 was a male infant who presented at 2 months
old with fever, vomiting and refusal of feeding. Examination revealed a sick-looking infant with signs of severe
dehydration and hypovolemic shock. He was jaundiced, and had hepatomegaly and elevated liver enzymes.
Echocardiography was performed in light of a lack of response to inotropes, and revealed biventricular and
interventricular septal hypertrophies. The ventricular ejection fraction was 65%. Urine organic acid analysis showed
elevated succinylacetone, consistent with a diagnosis of TT1. An FAH gene study identified a c.1 A > G homozygous
mutation. This patient responded well to intensive cardiorespiratory therapy, tyrosine-free formula, and oral
2-nitro-4- trifluoromethylbenzyl 1, 3 cyclohexanedione (NTBC). Echocardiographic findings reverted to normal
after 4 weeks. Case 2 was the younger brother of Case 1, and was born 6 months after his brother had been
confirmed with tyrosinemia. Pregnancy and delivery were uneventful. Serum amino acid and organic acid analyses
4 days after birth confirmed tyrosinemia. DNA analysis identified a c.1 A > G homozygous mutation, as in his
brother. Echocardiography was normal. Special formula and NTBC were commenced on day 7 of life. The infant
remained asymptomatic after 9 months of follow-up.
Conclusions: These cases highlight TT1 as a treatable cause of cardiomyopathy in children. It also supports the idea
that early diagnosis and treatment may prevent the development of cardiomyopathy associated with tyrosinemia.
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Tyrosinemia type 1(TT1) is an autosomal recessive disorder
caused by deficiency of the enzyme fumarylacetoacetate
hydrolase (FAH), which catabolizes fumyralacetoacetate
into fumarate and acetoacetate [1]. The pathophysiology
of the disease is explained by the subsequent accumula-
tion of tyrosine and its metabolite succinylacetone in the
liver, kidney and peripheral nerves, leading to dysfunction
of these organs [1,2]. TT1 usually presents in early infancy
with failure to thrive, vomiting, jaundice, hepatomegaly,
elevated liver enzymes and bleeding tendency [3]. Late
clinical features of TT1 include peripheral neuropathy,* Correspondence: sararmohamed@hotmail.com
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[1]. Cardiomyopathy is a rare condition in childhood [4],
and the Pediatric Cardiomyopathy Registry (PCMR) esti-
mated the incidence of childhood cardiomyopathy in the
United States to be 1.13 cases per 100,000 children [4].
Cardiomyopathy may be the predominant finding in a
number of inborn errors of metabolism, including mito-
chondrial disorders, glycogen storage disorders, carnitine
transporter defects, fatty acid oxidation defects and
lysosomal storage diseases [4,5], and some studies have
reported cardiomyopathy as an unusual and rare manifest-
ation of TT1 [6-9]. Herein we report two Saudi brothers
with TT1. The older sibling presented with hypertrophic
cardiomyopathy but responded well to medical treatment,
while the second infant remained asymptomatic after
being diagnosed by selective screening.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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Figure 1 M mode measurements revealing an interventricular
septum size of 0.59 cm before treatment.
Figure 2 M mode measurements revealing an interventricular
septum size of 0.42 cm after treatment.
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Case 1 was a previously well, 2-month-old Saudi boy
born to first cousin parents. The couple had two other
children, one of whom had died in early infancy with an
unexplained acute febrile illness. The patient was born
following an uneventful pregnancy and delivery. He
presented with a 2-day history of fever, poor feeding,
difficulty in breathing and lethargy. His weight, length
and head circumference were < 5th centile. Physical exam-
ination revealed a pale, sick-looking infant with prolonged
capillary refill time and cold extremities. He had a de-
pressed anterior fontanel, dry mucus membranes and
sunken eyes. Cardiac and respiratory examinations re-
vealed tachypnea, tachycardia, intercostal and subcostal
recessions, and no added sounds. Abdominal examin-
ation showed a soft non-tender hepatomegaly with a liver
span of 7 cm. A provisional diagnosis of septic shock was
entertained. Following routine blood samples, the patient
received fluid resuscitation and was commenced on
intravenous broad-spectrum antibiotics. The results of
complete blood count, serum glucose and renal functions
were within normal limits. Arterial blood gas showed
compensated mild metabolic acidosis. Liver function tests
revealed albumin 18 g/L (normal range, 30–50 g/), alanine
aminotransferase 40 U/L (normal range, 20–65 U/L),
aspartate aminotransferase 65 U/L (12–37 U/L), alkaline
phosphatase 3,547 U/L (normal range, 175–476 U/L), total
bilirubin 135 μmol/L (normal range, 2–22 μmol/L) and
direct bilirubin 61 μmol/L (normal range, 0–5 μmol/L).
Coagulation profile showed prothrombin time 44.2 s
(normal range, 11.5–16.5 s), activated partial thrombo-
plastin time 84.9 s (normal range, 26–39 s) and inter-
national normalized ratio 4.78 (normal range, 0.3–1.3).
Serum calcium and phosphorus levels were normal, serum
25-hydroxyvitamin D was low, and a wrist X- ray showed
osteopenia; consistent with vitamin D-deficiency rickets.
Echocardiography (Figures 1, 2 and 3) revealed situs
solitus, levocardia, concentric biventricular hypertrophy,
interventricular septal hypertrophy, mild dilated right
atrium and a small, muscular ventricular septal defect.
The ventricular ejection fraction was 65%. Metabolic
liver disease was suspected on the basis of hepatomegaly,
metabolic acidosis, elevated liver enzymes and coagulopathy,
and an extensive workup was arranged. Ammonia, lactate,
acylcarnitine profile, and galactose-1-phosphate uridyl
transferase were normal. Serum amino acid analysis
showed tyrosine 440 mmol/L (normal value, < 200 mmol/L),
methionine 358 mmol/L (normal value < 63 mmol/L),
phenylalanine 188 mmol/L (normal value < 180 mmol/L).
Urine organic acid analysis revealed elevated succinyl-
acetone, 15.9 mmol/L (normal value < 0.98 mmol/L), which
was consistent with a diagnosis of TT1. An FAH gene study
confirmed the presence of a homozygous c.1 A >G muta-
tion. The parents were both heterozygotes for the samemutation. The patient received cardiopulmonary sup-
port in the form of mechanical ventilation, dopamine,
dobutamine and epinephrine infusion. Specific treat-
ment measures for TTI commenced on the third day of
admission, including the use of tyrosine-free formula
and 2-Nitro-4-trifluoromethylbenzyl 1, 3 cyclohexanedione
(NTBC) administered at 1 mg/kg/day in two divided doses.
One week later, the patient was self-ventilating in room
air, and all inotropes had been discontinued. After a fur-
ther week, the patient’s liver function tests and coagulation
study results had reverted to normal. Echocardiographic
changes normalized after 4 weeks.
Case 2 was a male sibling of Case 1, who was born
6 months after the diagnosis of tyrosinemia had been
established in his brother. Pregnancy and delivery were
uneventful. Serum amino acid and organic acid analyses
4 days after birth confirmed TT1. A DNA study identi-
fied the same c.1 A > G homozygous mutation as in his
brother. Echocardiography was normal. Tyrosine-free
formula and NTBC were commenced on day 7 of life.
Figure 3 Long axis view revealing improvement in interventricular septum thickness with treatment.
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follow-up.Discussion
TT1 is a rare metabolic disorder with an estimated inci-
dence of 1 in 100,000–120,000 births worldwide [1]. TT1
is more common in some regions such as Quebec prov-
ince in Canada [1,10], but there are no epidemiological
data regarding the incidence of TT1 in the Middle East,
including Saudi Arabia. However, hospital-based case
series and reports from the Middle East, together with
the high incidence of consanguinity, suggest that TT1
may be more common than generally believed [2,3,11,12].
In this report, we present two siblings affected by TT1;
one diagnosed after presenting with a life-threatening con-
dition, and the other who remained asymptomatic after
being diagnosed by selective screening. The diagnosis of
TTI in both these patients was based on elevated serum
tyrosine levels and the detection of succinylacetone in the
urine [2]. The diagnosis was confirmed by the identifica-
tion of a pathogenic mutation in the FAH gene, which has
previously been described in patients from Saudi Arabia
and other countries [11,12].
Infants with TT1 usually present in the first few months
of life with prolonged jaundice, hepatopathy and failure to
thrive [1,3]. Our first patient presented with sepsis-like
features and hepatic impairment, including elevated liver
enzymes and coagulopathy. This highlights the import-
ance of considering acute metabolic disorders such as
tyrosinemia and galactosemia in children who present
with unexplained sepsis-like symptoms, especially in the
presence of hepatic impairment. Liver damage in TT1 is
secondary to the accumulation of the intermediate toxic
metabolite fumarylacetoacetate, which results in severe im-
pairment of clotting factor synthesis, leading to bleeding di-
athesis [13,14]. This process is usually triggered by
infections or catabolic stress.The presence of vitamin D-deficiency rickets in this
patient was notable. In contrast, TT1 is known to cause
rickets secondary to renal tubular defects as a late
manifestation of the disease, which was not seen in our
2-month-old infant. Moreover, the primary biochemical
findings in renal rickets associated with tyrosinemia are
low serum phosphate and increased urinary phosphate
excretion, which were also absent in our patient.
Childhood cardiomyopathy (CM) caused by inborn
errors of metabolism is rare [4]. However, CM associated
with TT1 has been reported in a few studies [6-9], and
Arora et al. reported CM in six out of 20 patients with
TT1 [6]. In agreement with our findings, Arora et al.
reported that cardiomyopathy associated with tyrosinemia
was benign and was associated with a favorable outcome
and complete resolution without recurrence in the vast
majority of cases [6]. Similar to Case 1 in the present
study, André et al. reported the successful treatment of
severe cardiomyopathy with NTBC in a patient with
TT1 [8]. Furthermore, Mohan et al. reported the complete
resolution of cardiomyopathy in three patients with TT1
after liver transplantation [9]. However, in contrast with
reports indicating a favorable prognosis of TT1-associated
cardiomyopathy, data from the PCMR suggest that hyper-
trophic cardiomyopathy associated with inborn errors of
metabolism carries a poorer prognosis [4]. This could
be explained by the fact that most patients with inborn
errors of metabolism included in the PCMR database
had mitochondrial disorders, which are known to carry
a poor prognosis, even in the absence of cardiomyopathy
[4]. As seen in Case 1, the type of cardiomyopathy associ-
ated with TT1 is usually hypertrophic cardiomyopathy, pre-
dominantly involving hypertrophy of the interventricular
septum [6-9]. It is interesting to note that most cases of
TT1-associated cardiomyopathy are reported at the initial
presentation of TT1, as in our first patient [6,7]. Moreover,
cardiomyopathy is significantly less common in patients
who receive initial treatment with NTBC [6]. Accordingly,
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in the initial assessment of new cases of TT1, especially if
they appear acutely sick or have an unexplained illness.
The pathogenesis of cardiomyopathy associated with
TT1 is poorly understood [6-8]. It may be related to ele-
vated tyrosine levels or to the accumulation of toxic
fumarylacetoacetate in the cardiac tissues. This view is
supported by the fact that cardiomyopathy resolves in most
patients treated with NTBC or liver transplantation [6-8].
It is interesting that the second infant we report here
did not have cardiomyopathy during 9 months of follow-
up after birth. This could be because this second infant
was diagnosed and treated early, before the development
of TT1-associated morbidity, including cardiomyopathy.
This suggests that cardiomyopathy secondary to TT1
may be an acquired, rather than a congenital condition.
However, this assumption could not be confirmed in the
first infant, because he did not receive an echocardio-
graphic examination during the asymptomatic neonatal
period. The evidence from these two cases indicates that
newborn screening for TT1 may prevent morbidity and
improve outcome.
Conclusions
We report two infants with TT1. One presented with
hypertrophic cardiomyopathy but responded dramatically
to tyrosine-free formula and NTBC. The second infant
was diagnosed during the first week of life and remained
asymptomatic after 9 months. This report highlights TT1
as a cause of treatable cardiomyopathy, and demonstrates
the value of screening for the early diagnosis of TT1 to
prevent associated morbidities.
Consent
Written informed consent was obtained from the parents
of the two siblings for publication of this Case Report and
any accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
Abbreviations
TT1: Tyrosinemia type 1; NTBC: 2-Nitro-4-trifluoromethylbenzyl 1, 3 cyclohexanedione.
Competing interests
All authors declare that they have no competing interests.
Authors’ contributions
SM designed the paper, collected the data, reviewed the literature, drafted
and reviewed the manuscript. MAK, NAA, AA, AB, RH and ASA participated in
data collection, writing and reviewing the manuscript. All authors read and
approved the final manuscript.
Authors’ information
Sarar Mohamed (SM) is a Fellow of the Royal College of Pediatrics and Child
Health. He is a consultant pediatric endocrinologist and Associate Professor
of Pediatrics at King Saud University in Saudi Arabia. Mohammed A. Kambal
(MAK) is a pediatric resident at King Saud University. Nasir A. Al Jurayyan
(NAA) MD is Professor of Pediatrics and a consultant pediatric
endocrinologist at King Saud University. Abdulrahman Al-Nemri (AA) MD is
Chairman of the Pediatric Department and Associate Professor of Pediatrics.Amir Babiker (AB) is a member of the Royal College of Pediatrics and Child
Health, Assistant Professor of Pediatrics, and a consultant pediatric
endocrinologist. Rana Hasanato (RH) MD is Assistant Professor of Pathology
and a consultant clinical chemist. Abdulla S. Al-Jarallah (ASA) MD is Professor
of Pediatrics and a consultant pediatric cardiologist.
Acknowledgements
The authors extend their appreciation to the College of Medicine Research
Center, Deanship of Scientific Research, King Saud University, Saudi Arabia,
for funding this work.
Author details
1Department of Pediatrics, College of Medicine, King Saud University, Riyadh
31461, P.O. Box 2925, Saudi Arabia. 2Department of Clinical Chemistry,
College of Medicine, King Saud University, Riyadh, Saudi Arabia. 3Cardiac
sciences Department, College of Medicine, King Saud University, Riyadh,
Saudi Arabia.
Received: 31 May 2013 Accepted: 4 September 2013
Published: 9 September 2013
References
1. Mitchell GA, Grompe M, Lambert M, Tanguay RM: In Hypertyrosinemia : the
metabolic and molecular bases of inherited disease. 5th edition. Edited by Scriver
CR, Beaudet A, Sly WS, Valle D. New York: McGraw Hill; 2001:1777–1806.
2. Rashed MS, Al-Ahaidib LY, Al-Dirbashi OY: Tandem mass spectrometric
assay of succinylacetone in urine for diagnosis of
hepatorenaltyrosinemia. Anal Biochem 2005, 339:310–317.
3. Rashad M, Nassar C: Tyrosinemia type 1: a case report. Sudan J Pediatr
2011, 11(1):64–67.
4. Wilkinson J, Sleeper L, Alvarez J, Bublik N, Lipshultz S: The pediatric
cardiomyopathy registry: 1995–2007. ProgPediatrCardiol 2008, 25(1):31–36.
5. Nugent AW, Daubeney PEF, Chondros P, Carlin JB, Cheung M, Wilkinson LC,
Davis AM, Kahler SG, Chow CW, Wilkinson JL, Weintraub RG: National Australian
childhood cardiomyopathy study.: the epidemiology of childhood
cardiomyopathy in Australia. N Engl J Med 2003, 348(17):1639–1646.
6. Arora N, Staper O, Wright J, Kelly D, Mckiernan P: Cardiomyopath in
tyrosinemia type 1 is common but usually benign. J Inherit Metab Dis
2006, 29:54–57.
7. Lindblad B, Fallstrom SP, Hoyer S, Nordborg C, Solymar L, Velander H:
Cardiomyopathy in fumarylscetoacetase deficiency (hereditary tyrosinemia): a
new feature of the disease. J Inherit Metab Dis 1987, 10(2):319–322.
8. Andre’ N, Roquelaure B, Jubin V, Ovaert C: Successful treatment of severe
cardiomyopathy with NTBC in a child with tyrosinemia type 1. J Inherit
Metab Dis 2005, 28(1):103–106.
9. Mohan N, McKiernan P, Preece MA, Green A, Buckels J, Mayer AD, Kelly DA:
Indications and outcome of liver transpalntaion in tyrosinemia type 1.
Eur J Pediatr 1999, 158(2):249–254.
10. De Braekeleer M, Larochelle J: Genetic epidemiology of hereditary
tyrosinemia in Quebec and in Saguenary-Lac-St-Jean. Am J Hum Genet
1990, 47:302–307.
11. Imtiaz F, Rashed M, Al Mubarak B, Allam R, El-Karaksy H, Al-Hassnan Z,
Al-Owain M, Al-Zaidan H, Rahbeeni Z, Qari A, Meyer BF, Al-Sayed M:
Identification of mutation causing hereditary TyrosinemiaType 1 in
patients of Middle Eastern origin. Mol Genet Metab 2011, 104(4):688–690.
12. Bergman AJ, van den Berg IE, Brink W, Poll-The BT, Ploos van Amstel JK,
Berger R: Spectrum of mutations in the fumarylacetoacetatehydrolase
gene of tyrosinemia type 1 patients in Northwestern Europe and
Mediterranean countries. Hum Mutat 1998, 12:19–26.
13. Croffie JM, Gupta SK, Chong SK, Fitzgerald JF: Tyrosinemia type 1 should
be suspected in infants with severe coagulopathy even in the absence
of other signs of liver failure. Pediatrics 1999, 103(3):675–678.
14. Georgouli H, Schulpis KH, Michelakaki H, Kaltsa M, Sdogou T, Kossiva L:
Persistent coagulopathy during Escherichia coli sepsis in a previously
healthy infant revealed undiagnosed tyrosinaemia type 1. BMJ Case Rep
2010, 2010:bcr0720103150. doi:10.1136/bcr.07.2010.3150.
doi:10.1186/1756-0500-6-362
Cite this article as: Mohamed et al.: Tyrosinemia type 1: a rare and
forgotten cause of reversible hypertrophic cardiomyopathy in infancy.
BMC Research Notes 2013 6:362.
